ILD year in review: Benefits of newer therapies, effects of air pollution, risk factors
The Healio Editors compiled the most-read interstitial lung disease news published in 2021.
Highlights from the previous year include new data on treatment options for ILD; rheumatoid-arthritis-associated ILD; antifibrotic medications for idiopathic pulmonary fibrosis; the effects of air pollution on fibrotic ILD; and more.
Read these articles, and others, below, in no particular order.
Nasal high-flow oxygen therapy yields benefit in severe ILD
Patients with severe ILD who received heated and humidified nasal high-flow oxygen therapy had significant improvements in endurance, physiologic parameters and sensations during exercise. Read more
Sustained reduction in lung function decline over longer-term with nintedanib in SSc-ILD
In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated ILD who continued nintedanib (Ofev, Boehringer Ingelheim) after completion of the SENSCIS trial maintained stable lung function or had improvement in lung function. Read more
IPF mortality in US decreased from 2004 to 2017
Age-adjusted mortality rates for IPF decreased from 2004 to 2017 in the United States, according to a study published in CHEST. Read more
Rheumatoid arthritis-ILD associated with excess mortality
Rheumatoid arthritis-related ILD was associated with significantly higher rates of excess mortality compared with the general population, according to new research published in BMC Pulmonary Medicine. Read more
Adoption of newer antifibrotic medications for IPF low in US in everyday practice: Study
Adoption of pirfenidone and nintedanib for the treatment of IPF has been low in the U.S., according to an analysis published in the Annals of the American Thoracic Society. Read more
Air pollution has various effects in fibrotic ILD
Air pollution has various effects on patients with fibrotic ILD, according to preliminary research presented at the PFF Summit. Read more
Gastroesophageal reflux disease may contribute to development of lung fibrosis
In a new study, the odds of having gastroesophageal reflux disease were nearly two times higher in patients with IPF compared with adults without IPF. Read more
Concomitant statin therapy yields benefit on IPF progression
Statin therapy may have a significant benefit on progression of IPF, according to results of a retrospective study published in Respiratory Medicine. Read more
Antifibrotic treatment may reduce mortality, acute exacerbations in IPF
In patients with IPF, antifibrotic treatment may reduce the risk for all-cause mortality and acute exacerbations, according to a systematic review and meta-analysis published in Chest. Read more
Adipose tissue may be a modifiable risk factor for ILD
Greater pericardial and abdominal visceral adipose tissue on CT scan was associated with early interstitial lung abnormalities and lower FVC in a study of community-dwelling adults, researchers reported in Chest. Read more